Who owns Amneal Pharmaceuticals, Inc. (AMAG)? Elite investor 13F holders
3 tracked elite investors reported holding Amneal Pharmaceuticals, Inc as of 2026-06-30, including Rubric Capital, D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | AMNEAL PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 176019505.00 USD | 10168660.000000 | Shares | reduce | Original filing |
| D.E. Shaw | AMNEAL PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 13398892.00 USD | 774055.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | AMNEAL PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1514400.00 USD | 87487.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | AMNEAL PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.